CERo Therapeutics (CERO) to Release Earnings on Wednesday

CERo Therapeutics (NASDAQ:CERO) is anticipated to post its results before the market opens on Wednesday, February 25th. Analysts expect CERo Therapeutics to post earnings of ($0.75) per share for the quarter.

CERo Therapeutics (NASDAQ:CERO) last announced its quarterly earnings results on Wednesday, November 19th. The company reported ($9.10) EPS for the quarter.

CERo Therapeutics Price Performance

NASDAQ CERO opened at $0.04 on Friday. The business’s fifty day moving average price is $0.06 and its 200-day moving average price is $2.45. The stock has a market capitalization of $832,120.00, a price-to-earnings ratio of 0.00 and a beta of 0.27. CERo Therapeutics has a 1-year low of $0.04 and a 1-year high of $39.68.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CERO. Maxim Group cut CERo Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, November 3rd. D. Boral Capital reiterated a “hold” rating on shares of CERo Therapeutics in a research note on Tuesday, November 18th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $45.00.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.